Argent Biopharma (ASX:RGT) FCF Margin % : -840.19% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Argent Biopharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Argent Biopharma's Free Cash Flow for the six months ended in Dec. 2023 was A$-7.92 Mil. Argent Biopharma's Revenue for the six months ended in Dec. 2023 was A$0.94 Mil. Therefore, Argent Biopharma's FCF Margin % for the quarter that ended in Dec. 2023 was -840.19%.

As of today, Argent Biopharma's current FCF Yield % is -87.80%.

The historical rank and industry rank for Argent Biopharma's FCF Margin % or its related term are showing as below:

ASX:RGT' s FCF Margin % Range Over the Past 10 Years
Min: -4822.5 Med: -525.2 Max: -313.84
Current: -786.45

During the past 13 years, the highest FCF Margin % of Argent Biopharma was -313.84%. The lowest was -4822.50%. And the median was -525.20%.

ASX:RGT's FCF Margin % is ranked worse than
95.8% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 0.13 vs ASX:RGT: -786.45

Argent Biopharma FCF Margin % Historical Data

The historical data trend for Argent Biopharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma FCF Margin % Chart

Argent Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

-1,023.78

-525.20

-516.94

-313.84

-359.65

Argent Biopharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-302.61	-327.15	-262.49	-716.55	-840.19

Competitive Comparison of Argent Biopharma's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argent Biopharma's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's FCF Margin % falls into.

Argent Biopharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Argent Biopharma's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-12.185	/	3.388
	=	-359.65 %

Argent Biopharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-7.923	/	0.943
	=	-840.19 %

Argent Biopharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Argent Biopharma (ASX:RGT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (ASX:RGT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MGCLF:USA MXC:UK H5O:Germany

Address

295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008

Website

https://mgcpharma.co.uk

MGC Pharmaceuticals Ltd is a biopharma company with a Nature to Medicine strategy at the forefront of the emerging phytocannabinoid and plant-derived medicine markets. The company's mission is to build an innovative, global bio-pharma company providing standardized, affordable plant-derived medicines of the highest regulatory compliance for targeted global markets.